Celltrion Receives Korean MFDS Approval to Initiate Phase I Trial of COVID-19 Antiviral Antibody Treatment Candidate, CT-P59, in Patients
Celltrion Group announced today that the Korean Ministry of Food and Drug Safety (MFDS) has approved the company’s Investigational New Drug (IND) application for a Phase I clinical trial of CT-P59, a COVID-19 antiviral antibody treatment candidate. Celltrion has initiated enrolment of patients with mild symptoms of SARS-CoV-2 infection and the clinical trial is set to evaluate the safety, tolerability, efficacy, pharmacokinetics and immunogenicity of CT-P59.
Celltrion anticipates global pivotal study results from the Phase II and III trials in patients with mild symptoms, the Phase III trial in patients with moderate-to-severe COVID-19, and the prevention clinical trial, by the end of the year. Celltrion plans to enrol people that are in close contact with COVID-19 patients and those with no symptoms as part of a prevention clinical trial to evaluate whether CT-P59 can elicit a neutralising antibody response to prevent the virus from infecting human cells.
“We have initiated an in-human global Phase I clinical trial of CT-P59 in mild COVID-19 patients and we plan to conduct further global Phase II and III trials in this patient group. In addition, Celltrion plans to combine Phase II and III trials in patients with moderate-to-severe COVID-19 with the prevention clinical trials.” said Dr. Sang Joon Lee, Senior Executive Vice President of Celltrion. “We are extremely encouraged by the consistent progress we are making in preparation for our CT-P59 clinical trials in various settings, and we remain on track to reach our upcoming milestones.”
In July, Celltrion initiated a Phase I trial of CT-P59 in the UK following the approval of the clinical trial authorisation (CTA) application from the UK Medicines and Healthcare products Regulatory Agency (MHRA). Celltrion has also completed an infusion and initial safety assessment for the Phase I study in healthy volunteers in Korea and the study is set for completion by Q3 this year as originally planned.
- ENDS -
Notes to Editors:
About Celltrion Healthcare
Celltrion Healthcare is committed to delivering innovative and affordable medications to promote patients’ access to advanced therapies. Its products are manufactured at state-of-the-art mammalian cell culture facilities, designed and built to comply with the US FDA cGMP and the EU GMP guidelines. Celltrion Healthcare endeavours to offer high-quality cost-effective solutions through an extensive global network that spans more than 110 different countries. For more information please visit: https://www.celltrionhealthcare.com/en-us
About COVID-191,2
Coronaviruses (CoV) are a family of viruses that lead to illnesses from the common cold to severe diseases. Novel coronavirus SARS-CoV-2 is responsible for the disease COVID-19, this new strain, discovered in 2019, is behind the ongoing pandemic outbreak.
The most common signs of COVID-19 include fever, dry cough and tiredness; however, people may also experience other symptoms including shortness of breath and breathing difficulties. Most people infected with the virus will exhibit mild to moderate symptoms however older people, and those with existing underlying conditions such as cardiovascular disease and diabetes are more likely to develop a more severe form of COVID-19.
Please find up to date information about the outbreak via the World Health Organization at https://www.who.int/health-topics/coronavirus#tab=tab_1
FORWARD LOOKING STATEMENT
Certain information set forth in this press release contains statements related to our future business and financial performance and future events or developments involving Celltrion/Celltrion Healthcare that may constitute forward-looking statements, under pertinent securities laws.
These statements may be identified by words such as “prepares”, “hopes to”, “upcoming”, ”plans to”, “aims to”, “to be launched”, “is preparing, “once gained”, “could”, “with the aim of”, “may”, “once identified”, “will”, “working towards”, “is due”, “become available”, “has potential to”, the negative of these words or such other variations thereon or comparable terminology.
In addition, our representatives may make oral forward-looking statements. Such statements are based on the current expectations and certain assumptions of Celltrion/Celltrion Healthcare's management, of which many are beyond its control.
Forward-looking statements are provided to allow potential investors the opportunity to understand management’s beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment. These statements are not guarantees of future performance and undue reliance should not be placed on them.
Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or result expressed or implied by such forward-looking statements.
Although forward-looking statements contained in this presentation are based upon what management of Celltrion/Celltrion Healthcare believes are reasonable assumptions, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Celltrion/Celltrion Healthcare undertakes no obligation to update forward-looking statements if circumstances or management’s estimates or opinions should change except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements.
References
1 Coronavirus. World Health Organization. Available at: https://www.who.int/health-topics/coronavirus#tab=tab_1 Last accessed: August 2020
2 Coronaviruses. National Institute of Allergy and Infectious Diseases. Available at: https://www.niaid.nih.gov/diseases-conditions/coronaviruses Last accessed: August 2020
View source version on businesswire.com: https://www.businesswire.com/news/home/20200826005516/en/
Contact information
Zuzanna Grzeskiewicz
zgrzeskiewicz@hanovercomms.com
+44 (0) 7506 339043
Sophia Eminson
seminson@hanovercomms.com
+44 (0) 7751 116252
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Matt Roney Named as Lumileds Chief Executive Officer21.9.2020 19:15:00 EEST | Press release
Lumileds, a global leader in innovative lighting solutions, today announced the appointment of Matt Roney as the company’s Chief Executive Officer, effective October 1, 2020. Roney most recently served as President of Lumileds’ Automotive Business Unit and succeeds Dr. Jonathan Rich who will continue with the company as Executive Chairman of the Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200921005130/en/ Matt Roney, CEO Lumileds (Photo: Business Wire) “Speaking on behalf of the Board of Directors, we are grateful for Jon’s contributions as CEO and believe Lumileds is well positioned for success in this next phase under Matt’s leadership,” said Rob Seminara, Senior Partner at Apollo Global Management. “Matt has nearly 25 years’ experience in the automotive industry and his performance and leadership throughout his career have given us even greater confidence in his ability to drive long-term innovation and growth a
Toshiba Information Systems (Japan) Integrates Verimatrix’s Whitebox Cryptographic Key Technology Into Customer’s Main Control Function to Safeguard Consumer Printers21.9.2020 18:45:00 EEST | Press release
Regulatory News: Verimatrix, (Paris:VMX) (Euronext Paris: VMX), the leader in powering the modern connected world with people-centered security, today announced that its value-added reseller, Japan-based Toshiba Information Systems (Japan) Corporation, has implemented Verimatrix Whitebox cryptographic key protection technology inside consumer printers produced by one of the country’s premier manufacturers. Whitebox is part of the Verimatrix Application Shielding family of solutions. "Exposed cryptographic keys are a significant vulnerability in IoT code for connected devices," said Asaf Ashkenazi, Chief Operating Officer at Verimatrix. "Our Whitebox tool allows Toshiba Information Systems (Japan) to dissolve keys into the code itself and obscures algorithms to keep its customer’s critical intellectual property, applications, devices and data safe. The deployment of our Whitebox technology into the devices of a leading electronics manufacturer illustrates our ability to easily empower p
RELX Outlines at the GTNF Role of Technology in Advancing Vaping Industry’s Responsible Practices21.9.2020 15:29:00 EEST | Press release
The company’s Global External Affairs Lead provided concrete examples of how RELX has been harnessing the power of technology, innovation and research in its quest to forge ahead robust youth prevention mechanisms. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200921005456/en/ Jonathan Ng speaking at the GTNF Innovations on the Horizon panel. (Photo: Business Wire) At the virtual Global Tobacco & Nicotine Forum (GTNF) event yesterday, RELX Technology’s Global Head of External Affairs Jonathan Ng spoke on a panel entitled “Innovations on the Horizon.” The panel explored several topics related to the growing international acceptance of e-cigarettes as better alternatives to cigarettes, innovations related to user experience and youth prevention, and illicit trade. GTNF is one of the leading tobacco and nicotine forums in the world; speakers and attendees include public health experts, government representatives, investors and
CHMP Grants Positive Opinion for Expanded Use of Otsuka’s Deltyba® (delamanid) in Children and Adolescents Weighing at Least 30kg Treated for Pulmonary Multi-drug Resistant Tuberculosis21.9.2020 14:12:00 EEST | Press release
Otsuka Novel Products GmbH (ONPG), a subsidiary of Otsuka Pharmaceutical Co., Ltd., is pleased to announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommends approval of extension of the indication for Deltyba® (delamanid) for children. This means Deltyba® (delamanid) is recommended by the CHMP for use as part of an appropriate combination regimen for pulmonary MDR-TB in adults, adolescents and children with a body weight of at least 30kg when an effective treatment regimen cannot otherwise be composed for reasons of resistance or tolerability. According to the current World Health Organization Global TB Report, an estimated 1.1 million children (0-14 years of age) fell ill with TB in 2018.2 Each year, approximately 25,000-32,000 children fall ill with MDR-TB. Of these, only 3-4% are diagnosed and treated and consequently, approximately 21% of children with MDR-TB are likely to die.1 New global targets set at the UNs High Le
Visa Helps Prepare Small Businesses for the Holiday Buying Season as National Small Business Week Begins21.9.2020 14:00:00 EEST | Press release
As the Small Business Administration’s (SBA) National Small Business Week begins in the U.S. and businesses worldwide prepare for an unprecedented holiday season, Visa (NYSE: V) is introducing new programs and resources essential to small and micro business (SMB) recovery efforts. The Visa Back to Business Study, Holiday Edition, launched today, finds that consumers will carry their resolve for normalcy into the holiday shopping season, with 88% planning to buy and give gifts despite challenges the pandemic has created. To prepare for this unprecedented holiday season, SMBs should be looking for ways to offset the impact of COVID-19 during the holidays, with 60% already saying they are taking steps to prepare. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200921005150/en/ Visa’s Back to Business kits include new “tap to pay preferred” point-of-sale materials, branding, educational resources and special offers. (Photo: Busin
"If Agroaceite Grows, Our Communities Grow, Too"21.9.2020 14:00:00 EEST | Press release
This is one of our principles at Agroaceite, as pointed out by José Javier Aguirre, Corporate Director of the tropical oil company. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200921005269/en/ Agroaceite's Human Development Center facilities. "Some time ago I had the opportunity to visit Agroaceite ́s medical center, which is managed in collaboration with the University of Colorado. I was pleasantly impressed by the high quality service offered to the surrounding community. This is a good example of the kind of impact that RSPO certification aims to achieve: to improve people’s quality of life within the company ́s area of influence." FRANCISCO NARANJO, RSPO Representative for Latin America. (Photo: Business Wire) "Since Agroaceite was founded, the vision of social responsibility has been clear. Our main asset is our employees, and our best allies are the communities. As Agroaceite succeeds, communities must develop to th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom